BULLFROG AI HOLDINGS

BullFrog AI’s VP Artificial Intelligence to Present at Google’s Cancer AI Symposium

22 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

21 Oct 2024 11:45:00 By Nasdaq GlobeNewswire

Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million

18 Oct 2024 09:30:54 By Nasdaq GlobeNewswire

BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

BullFrog AI to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

26 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI and Lieber Institute for Brain Development Reveal New Insights into Bipolar Disorder Pathways and Potential Drug Targets

25 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on June 12

29 May 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI and Lieber Institute for Brain Development Collaboration Identifies Novel Drug Targets for Neuropsychiatric Disorders

16 May 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI’s CSO, Tom Chittenden, to Present at the Quantum Computing Symposium at Bio-IT World Conference & Expo

09 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI Announces Availability of Fireside Chat Recording Featuring CEOs of BullFrog AI and the Lieber Institute

08 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer

26 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI Announces Underwriter’s Decision to Exercise Over-Allotment Option to Purchase 218,382 Shares of the Company’s Common Stock

21 Feb 2024 12:01:05 By Nasdaq GlobeNewswire

BullFrog AI to Discuss Findings from its Collaboration with Lieber Institute for Brain Development in Fireside Chat Hosted by RedChip

09 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI Announces Closing of $5.7 Million Public Offering

05 Feb 2024 10:00:57 By Nasdaq GlobeNewswire

Bullfrog AI Announces Pricing of $5.7 Million Public Offering

01 Feb 2024 09:00:00 By Nasdaq GlobeNewswire

BullFrog AI Strengthens Scientific Advisory Board with the Addition of Dr. Gwenn Smith and Dr. Jeremiah Wala

26 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

BullFrog AI’s Collaboration with Lieber Institute for Brain Development Yields Potentially Groundbreaking Biological Stratification of Brain Expression Data

17 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

BullFrog AI Announces Issuance of Australian Patent Protecting Novel Prodrugs of Mebendazole and Their Use in Treating Cancer

16 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

BullFrog AI to Present at Webull LIVE! Healthcare Webinar on January 17

11 Jan 2024 16:05:00 By Nasdaq GlobeNewswire